Avexa mulls options as it closes lead HIV programme for apricitabine
This article was originally published in Scrip
Executive Summary
Australian biotech Avexa said it would explore strategic alternatives for the company after ceasing further development of its lead HIV programme for its NRTI apricitabine (ATC), following unsuccessful partnering discussions with global pharmaceutical companies. Shares in the company plummeted by 78% on the news to close at 3 Australian cents on 10 May.